Asia ground zero for Alcon turnaround plans with China a focus

Novartis

Novartis ($NVS) CEO Joe Jimenez changed management teams at troubled eye care unit Alcon this year and brought in former Hospira CEO Mike Ball, who said plans are afoot for a turnaround and specifically discussed the state-of-play in Asia.

On the July 19 earnings call, analysts zeroed in on Alcon with questions on weakness in sales of Intraocular lenses (IOLs) in Asia, a key market for the unit in countries such as China, India and Japan.

"So, with respect to Asia then--so we are in fact looking into this weakness," Ball said on the call.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

"Preliminarily, what I think it is, is some issues with distributors both in China and India. We also though clearly are having issues from an ASP (average selling point) standpoint, which is impacting us. Now, we do have new management teams on the ground there since the end of last year, beginning of this year. So I expect that as we move through the year, we'll get some resolution in terms of what exactly is going on here and what exactly we can do about it."

The unit missed expectations in the second quarter, though Jimenez had warned there would be no quick fix as Ball took over from Jeff George on Feb. 1, with a focus on the Surgical and Vision Care business.

But the slow start led to questions that Ball parried with comments that suggested the unit may spend more to bring about a turnaround.

"With respect to Alcon, obviously, our number one objective here is to return the top line to growth," Ball said.

"To do that, as I've mentioned before, we need to make investments both in the marketing and sales and innovation side, which then necessarily impacts the bottom line. So ... over the longer term, our objective is to get back to this low 20s to mid 20s operating income. But in the interim, you're going to see a reduction in terms of operating income as we work towards getting this top line back on track."

In June of last year, two key Alcon executives in Asia left the firm, Roy Acosta, Asia & Russia region president, and Jim West, Asia & Russia chief financial officer, sparking a wider review of operations in the region.

- here's the Novartis financial report

Related Articles:
Novartis warns profits may decline on Gleevec copies, spending boost for Entresto, Cosentyx
Novartis CEO eyes biosimilar plays in Asia that fit with Sandoz plans
Novartis hit on Gleevec in U.S. tells the tale for India's Sun Pharma
In regional shakeup, Novartis' Alcon fires two Asia execs

Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.